

Ulcerative Colitis and Crohn's Disease Committee meeting

Date: 17/04/2018

Location: Manchester

Minutes: Final

Committee members present:

Tessa Lewis (Chair)	(Present for items 1 – 8)
Charmian Banks	(Present for items 1 – 8)
Sarah Cripps	(Present for items 1 – 8)
Jenny Epstein	(Present for items 1 – 8)
Joan Gavin	(Present for items 1 – 8)
Richard Harris	(Present for items 1 – 8)
Sophia Joseph	(Present for items 1 – 8)
Themba Mudege	(Present for items 1 – 8)
Thomas Mytton	(Present for items 1 – 8)
Robert Palmer	(Present for items 1 – 8)
Megan Prydderch	(Present for items 1 – 8)

In attendance:

Omnia Abdulrazeg	Technical Analyst	(Present for items 1 – 8)
Chris Carmona	Senior Technical Analyst	(Present for items 1 – 8)
Susannah Gyton-Moon	Programme Manager	(Present for items 1 – 8)
Caroline Keir	NICE - Guideline Commissioning Manager	(Present for items 1 – 8)
Bernadette Li	Technical Advisor – Health Economics	(Present for items 1 – 8)
Rui Martins	Technical Analyst	(Present for items 1 – 8)
Gabriel Rogers	Technical Advisor - Health Economics	(Present for items 1 – 8)

Apologies:

Rachel Cooney	Committee Member
Bruce George	Committee Member
Janindra Warusavitarne	Committee Member

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the fourth meeting

on Ulcerative Colitis and Crohn's Disease. The Committee members and attendees introduced themselves.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included: a recap of the clinical and economic evidence for the ulcerative colitis review question on the clinical and cost-effectiveness of corticosteroids, aminosalicylates, immunomodulators (methotrexate, mycophenolate and tacrolimus) for the induction of remission compared to themselves (different preparations and doses), each other, combinations of preparations (oral and topical) and placebo; and a consideration of the initial results of the evidence for Crohn's disease for the review question: in adults and children what is the clinical and cost effectiveness of medical and/or nutritional treatment for post-surgical (commencing within three months of any intestinal surgery for Crohn's disease) maintenance of remission for 12 months or longer?

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest the matter under discussion is the clinical and cost-effectiveness of corticosteroids, aminosalicylates, immunomodulators (methotrexate, mycophenolate and tacrolimus) for the induction of remission compared to themselves (different preparations and doses), each other, combinations of preparations (oral and topical) and placebo and the clinical and cost effectiveness of medical and/or nutritional treatment for post-surgical (commencing within three months of any intestinal surgery for Crohn's disease).

The Chair asked everyone to verbally declare any interests. The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

3. Presentations – Ulcerative Colitis clinical evidence results

The Chair introduced Gabriel Rogers, health economist, who presented the results of the analysis for the review question. The Chair introduced Omnia Abdulrazeg, technical analyst, who presented the reviewed network meta-analysis for the clinical review with updated dosage levels.

The Chair thanked Gabriel and Omnia for their presentations. The Committee discussed the results in relation to the draft recommendations.

4. Presentations - Ulcerative Colitis health economic results

The Chair introduced Bernadette Li, health economist, who discussed with the Committee the details of the economic analysis.

The Chair thanked Bernadette for their presentation.

5. Committee discussion – drafting recommendations

The committee were given the opportunity to ask questions about the evidence presented, and discussed draft recommendations.

The committee drafted recommendations and research recommendations.

6. Presentations – Crohn’s disease

Omnia Abdulrazeg, technical analyst, and Bernadette Li, health economist, discussed the pairwise analysis for Crohn’s disease and how these initial findings will contribute to the economic model and further data analysis for this review question.

The Committee were given the opportunity to ask questions and all discussed the next steps in the analysis.

7. AOB

There were no items for AOB.

8. Summary and next steps

Susannah Gyton-Moon, programme manager, informed the Committee that they will be asked to comment on the evidence review and short guideline in the coming weeks before it is submitted for quality assurance. Susannah also clarified future Committee meeting dates.

The Chair advised the date of the next meeting (see below) and thanked the committee for their attendance and closed the meeting.

Date of next meeting: 22/06/2018

Location of next meeting: London